The new extension will create over 250 skilled jobs and support global pharmaceutical markets
Pfizer has officially opened its S$1 billion extension at its Tuas site in Singapore, aiming to produce active pharmaceutical ingredients (APIs) for its oncology, pain, and antibiotic medications. This highly automated facility, which spans 429,000 square feet, is set to create more than 250 skilled jobs by 2026, with 230 roles already filled, and 80% of the workforce consisting of local talent.
The Tuas II facility will manufacture 11 types of APIs, seven of which are already produced at the company’s original Tuas site. These include an API used in Ibrance, a leading drug for breast cancer treatment. The production of the remaining four APIs will shift to Singapore from Pfizer’s initial site in Ringaskiddy, Ireland.
Paul Smullen, Pfizer’s site lead, emphasized that the company is hiring across various sectors, including production, quality, and engineering. The new site will serve global markets, including China, Brazil, Japan, Turkey, Europe, and the U.S.
Minister for Trade and Industry Gan Kim Yong noted that Pfizer is the largest contributor to Singapore’s pharmaceutical manufacturing output and expressed the government’s commitment to maintaining Singapore as a top destination for pharmaceutical investments.
This new extension aligns with Singapore’s Manufacturing 2030 vision, which aims to position the nation as a global leader in advanced manufacturing. Jacqueline Poh, managing director of the Singapore Economic Development Board, highlighted that Pfizer’s investment reinforces Singapore’s status as a key biomedical hub, contributing to the country’s economic growth and preparedness for future public health challenges.
